bullish

VolitionRX

VNRX: Reports 3Q 2024 results. Over 110

174 Views04 Dec 2024 23:00
Issuer-paid
Volition's Nu.Q Vet Canine Cancer Screening Test now available in 17 countries, particularly by Antech on its Element I+ diagnostic...
What is covered in the Full Insight:
  • Introduction
  • 3Q 2024 Financial Results
  • Operational Updates
  • Licensing Efforts and R&D
  • Valuation and Outlook
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 21-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Zacks Small Cap Research
Research Coverage on Small and Micro-Cap Companies
Zacks Small Cap Research
Equity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x